Currently, the first prospective clinical trial (National Clinical Trial number (NCT) at Clinicaltrals.gov: NCT06059014) titled Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients with Metastatic Clear Cell Renal Cancer (PRadR) has begun enrollment and is expected to provide data on the safety and efficacy of RLT with [177Lu]Lu-PSMA-1 in ccRCC. The gene discussed is FOLH1; the disease is nonpapillary renal cell carcinoma.